Literature DB >> 6381547

Morphological and immunohistological changes in the skin in allogeneic bone marrow recipients.

J P Sloane, J A Thomas, S F Imrie, D F Easton, R L Powles.   

Abstract

Skin biopsies from leukaemic patients undergoing allogeneic bone marrow transplantations and treated prophylactically with cyclosporin A were analysed using histological, morphometric, and immunohistological techniques. Samples from donors were used to establish normal values. Biopsies taken from recipients two days before grafting were all histologically normal, but on immunohistological staining half of them showed a reduction in the number of epidermal Langerhans' cells and 29% a reduction in T inducer lymphocytes. Thirty two biopsies were taken from patients with rashes at various times after transplantation: 14 showed lichenoid changes consistent with graft versus host disease, three eczematous tissue reactions, two vesicular lesions, and 12 no histological abnormality. One sample showed changes intermediate between the lichenoid and eczematous forms. The numbers of epidermal Langerhans' cells were low during the first few weeks after transplantation and were normal or raised later regardless of histological appearances. Unlike epidermal Langerhans' cells, significant reductions in the numbers of lymphocytes were not seen. Lesions of all histological types contained mixtures of T inducer and T suppressor/cytotoxic cells, although the eczematous and vesicular lesions contained higher proportions of T inducer cells. Epidermal infiltrates invariably contained T suppressor/cytotoxic cells but infiltration of epidermis by T inducer cells occurred only in the presence of normal numbers of epidermal Langerhans' cells. Natural killer cells were not identified. The immunological appearances of the various histological subgroups thus change with time after transplantation.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6381547      PMCID: PMC498892          DOI: 10.1136/jcp.37.8.919

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  25 in total

1.  A study of the epidermal clear cells with special reference to their relationship to the cells of Langerhans.

Authors:  J FAN; R J SCHOENFELD; R HUNTER
Journal:  J Invest Dermatol       Date:  1959-03       Impact factor: 8.551

2.  The psoriasiform eruption induced by practolol.

Authors:  R E Cochran; J Thomson; K Fleming; A McQueen
Journal:  J Cutan Pathol       Date:  1975       Impact factor: 1.587

Review 3.  Monoclonal antibodies for analysis of the HLA system.

Authors:  F M Brodsky; P Parham; C J Barnstable; M J Crumpton; W F Bodmer
Journal:  Immunol Rev       Date:  1979       Impact factor: 12.988

4.  The skin biopsy in the diagnosis of acute graft-versus-host disease in man.

Authors:  G E Sale; K G Lerner; E A Barker; H M Shulman; E D Thomas
Journal:  Am J Pathol       Date:  1977-12       Impact factor: 4.307

5.  Early secondary disease in the Rhesus monkey. I. A comparative histopathologic study.

Authors:  J M Woodruff; J R Eltringham; H W Casey
Journal:  Lab Invest       Date:  1969-06       Impact factor: 5.662

6.  A differentiation antigen of human NK and K cells identified by a monoclonal antibody (HNK-1).

Authors:  T Abo; C M Balch
Journal:  J Immunol       Date:  1981-09       Impact factor: 5.422

7.  Expression of Ia antigen on epidermal keratinocytes in graft-versus-host disease.

Authors:  I A Lampert; A J Suitters; P M Chisholm
Journal:  Nature       Date:  1981 Sep 10-16       Impact factor: 49.962

8.  Histopathology of graft-vs.-host reaction (GvHR) in human recipients of marrow from HL-A-matched sibling donors.

Authors:  K G Lerner; G F Kao; R Storb; C D Buckner; R A Clift; E D Thomas
Journal:  Transplant Proc       Date:  1974-12       Impact factor: 1.066

9.  Differential diagnosis of malignant lymphoma and nonlymphoid tumors using monoclonal anti-leucocyte antibody.

Authors:  G Pizzolo; J Sloane; P Beverley; J A Thomas; K F Bradstock; S Mattingly; G Janossy
Journal:  Cancer       Date:  1980-12-15       Impact factor: 6.860

10.  Epidermal Langerhans cells are derived from cells originating in bone marrow.

Authors:  S I Katz; K Tamaki; D H Sachs
Journal:  Nature       Date:  1979-11-15       Impact factor: 49.962

View more
  8 in total

1.  T lymphocytes expressing HECA-452 epitope are present in cutaneous acute graft-versus-host disease and erythema multiforme, but not in acute graft-versus-host disease in gut organs.

Authors:  R E Davis; B R Smoller
Journal:  Am J Pathol       Date:  1992-09       Impact factor: 4.307

Review 2.  Treatment of lichen planus.

Authors:  G F Oliver; R K Winkelmann
Journal:  Drugs       Date:  1993-01       Impact factor: 9.546

3.  Drug-induced skin reactions and acute cutaneous graft-versus-host reaction: a comparative immunohistochemical study.

Authors:  M Drijkoningen; C De Wolf-Peeters; G Tricot; H Degreef; V Desmet
Journal:  Blut       Date:  1988-02

4.  Langerhans' cells are depleted in chronic graft versus host disease.

Authors:  S Aractingi; E Gluckman; M C Dauge-Geffroy; C Le Goué; A Flahaut; L Dubertret; E Carosella
Journal:  J Clin Pathol       Date:  1997-04       Impact factor: 3.411

5.  Changes in rectal leucocytes after allogeneic bone marrow transplantation.

Authors:  S A Dilly; J P Sloane
Journal:  Clin Exp Immunol       Date:  1987-01       Impact factor: 4.330

6.  Immunoelectron microscopy of acute graft versus host disease of the skin after allogeneic bone marrow transplantation.

Authors:  M Takata; T Imai; T Hirone
Journal:  J Clin Pathol       Date:  1993-09       Impact factor: 3.411

7.  An immunohistological study of human hepatic graft-versus-host disease.

Authors:  S A Dilly; J P Sloane
Journal:  Clin Exp Immunol       Date:  1985-12       Impact factor: 4.330

8.  The fate of human Langerhans cells in hematopoietic stem cell transplantation.

Authors:  Matthew P Collin; Derek N J Hart; Graham H Jackson; Gordon Cook; James Cavet; Stephen Mackinnon; Peter G Middleton; Anne M Dickinson
Journal:  J Exp Med       Date:  2006-01-03       Impact factor: 14.307

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.